GVS advice on dabigatran etexilate (Pradaxa®) capsules extension further conditions
The National Health Care Institute has completed its assessment whether the further conditions for the reimbursement of dabigatran etexilate (Pradaxa®) capsules can be extended for a paediatric application. The National Health Care Institute advises the Minister to amend List 2 of the GVS.
Indication for which extension of the reimbursement conditions is requested
The applicant proposes extending the further conditions for dabigatran to include the group of insured persons aged 8 to 18 who are reliant on this medicine for the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE.
National Health Care Institute's advice
Dabigatran is already included on List 1A with further conditions for adults. The National Health Care Institute advises the Minister to amend List 2 of the GVS. For dabigatran, the condition can be extended as follows:
140. Dabigatran
Condition
only for insured persons 2 aged 8 to 18 who are reliant on this medicine for the treatment of venous thromboembolism (VTE) and the prevention of recurrent VTE after parenteral anticoagulation treatment lasting at least 5 days.